153 related articles for article (PubMed ID: 32224563)
1. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
[No Abstract] [Full Text] [Related]
2. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
3. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Ong SY; Phipps C; Kaur H; Tan L; Lee YS
Ann Acad Med Singap; 2019 Sep; 48(9):298-300. PubMed ID: 31737895
[No Abstract] [Full Text] [Related]
4. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
5. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
[TBL] [Abstract][Full Text] [Related]
6. Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.
Hong JY; Yoon DH; Yoon SE; Kim SJ; Lee HS; Eom HS; Lee HW; Shin DY; Koh Y; Yoon SS; Jo JC; Kim JS; Kim SJ; Cho SH; Lee WS; Won JH; Kim WS; Suh C
Sci Rep; 2019 Dec; 9(1):20302. PubMed ID: 31889144
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
8. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
9. Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report.
Lolli G; Casadei B; Pellegrini C; Argnani L; Cocito F; Zinzani PL
Tumori; 2021 Dec; 107(6):NP105-NP107. PubMed ID: 34167407
[TBL] [Abstract][Full Text] [Related]
10. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
12. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z; Sara Mohamed J; Salma A; Francine F
Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): preliminary results from the T-Cell Consortium trial.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):6-7. PubMed ID: 24852788
[No Abstract] [Full Text] [Related]
14. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
15. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
Hui J; Przespo E; Elefante A
J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
[TBL] [Abstract][Full Text] [Related]
16. Optimizing chemotherapeutic strategies for peripheral T-cell lymphomas.
Rosenstein LJ; Link BK
Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S180-6. PubMed ID: 19073525
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial.
Park S; Kim AY; Cho H; Baik D; Lee H; Cho S; Kang HY
BMC Cancer; 2020 Nov; 20(1):1157. PubMed ID: 33243162
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.
Ogura M; Tsukasaki K; Nagai H; Uchida T; Oyama T; Suzuki T; Taguchi J; Maruyama D; Hotta T; Tobinai K
Cancer Sci; 2012 Jul; 103(7):1290-5. PubMed ID: 22448814
[TBL] [Abstract][Full Text] [Related]
20. Hematology: relapsed and refractory PTCL--into the therapeutic abyss.
Foss F
Nat Rev Clin Oncol; 2011 Jun; 8(6):321-2. PubMed ID: 21468128
[No Abstract] [Full Text] [Related]
[Next] [New Search]